Global BioAccess Fund
Venture capitalNew York · Series A–Late Stage · 5 people tracked
Investment thesis
Global BioAccess Fund invests in early-stage biotech companies developing therapeutics for oncology, cardiovascular disease, central nervous system disorders, and rare diseases, with a focus on funding through investigational new drug applications and clinical trial phases.
Team · 5 people
from the firm's websiteFrequently asked questions
- What stage does Global BioAccess Fund invest at?
- Global BioAccess Fund invests at the Series A, Series B, Series C, Late Stage stages.
- What is Global BioAccess Fund's typical check size?
- Global BioAccess Fund typically writes checks of $10M.
- What sectors does Global BioAccess Fund focus on?
- Global BioAccess Fund focuses on Biotech, Medical Devices.
- Where is Global BioAccess Fund located?
- Global BioAccess Fund is headquartered in New York, US.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
Khosla Ventures is a technology-focused investment firm that seeks companies leveraging disruptive technological advances to solve large-scale problems across multiple industries. The firm emphasizes proprietary technology, business model innovation, and early-stage, bold investments with unfair advantages.
EQT Life Sciences is one of Europe's largest and most experienced life sciences investors, focusing on innovative companies developing therapeutics, medical devices, diagnostics, and healthtech globally. The firm has raised approximately 3.5 billion euros across 12 private funds and 3 investment strategies over its 30-year history.